This article is more than 5 years old. Information may no longer be current.

OcuGene gains Italian distributor

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ALAMEDA, Calif. — OcuGene, a genetic test for glaucoma, will be distributed in Italy by SIFI SpA, according to InSite Vision, the test’s developer. An 8-year distribution agreement gives exclusive rights to SIFI, which plans to introduce OcuGene in Italy during the second half of 2003, once it has finalized premarketing and internal support for the product.

This marks the first international agreement for distribution of OcuGene, said S. Kumar Chandrasekaran, PhD, InSite’s president and chief executive officer.

OcuGene is a proprietary system of genetic testing for primary open-angle glaucoma. It screens for the TIGR mt-1 variant. People with this variant tend to have a more aggressive form of glaucoma and have shown more visual field damage than patients without the variant.